FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009702208> ?p ?o ?g. }

• W2009702208 endingPage "3391" @default.
• W2009702208 startingPage "3384" @default.
• W2009702208 abstract "Radiofluorinated benzamide and nicotinamide analogues are promising molecular probes for the positron emission tomography (PET) imaging of melanoma. Compounds containing aromatic (benzene or pyridine) and N,N-diethylethylenediamine groups have been successfully used for development of melanin targeted PET and single-photon emission computed tomography (SPECT) imaging agents for melanoma. The objective of this study was to determine the feasibility of using aliphatic compounds as a molecular platform for the development of a new generation of PET probes for melanoma detection. An aliphatic N,N-diethylethylenediamine precursor was directly coupled to a radiofluorination synthon, p-nitrophenyl 2-18F-fluoropropionate (18F-NFP), to produce the probe N-(2-(diethylamino)ethyl)-2-18F-fluoropropanamide (18F-FPDA). The melanoma-targeting ability of 18F-FPDA was further evaluated both in vitro and in vivo through cell uptake assays, biodistribution studies, and small animal PET imaging in C57BL/6 mice bearing B16F10 murine melanoma tumors. Beginning with the precursor 18F-NFP, the total preparation time for 18F-FPDA, including the final high-performance liquid chromatography purification step, was approximately 30 min, with a decay-corrected radiochemical yield of 79.8%. The melanin-targeting specificity of 18F-FPDA was demonstrated by significantly different uptake rates in tyrosine-treated and untreated B16F10 cells in vitro. The tumor uptake of 18F-FPDA in vivo reached 2.65 ± 0.48 %ID/g at 2 h postinjection (p.i.) in pigment-enriched B16F10 xenografts, whereas the tumor uptake of 18F-FPDA was close to the background levels, with rates of only 0.37 ± 0.07 %ID/g at 2 h p.i. in the nonpigmented U87MG tumor mouse model. Furthermore, small animal PET imaging studies revealed that 18F-FPDA specifically targeted the melanotic B16F10 tumor, yielding a tumor-to-muscle ratio of approximately 4:1 at 1 h p.i. and 7:1 at 2 h p.i. In summary, we report the development of a novel 18F-labeled aliphatic compound for melanoma imaging that can be easily synthesized in high yields using the radiosynthon 18F-NFP. The PET probe 18F-FPDA exhibits high B16F10 tumor-targeting efficacy and favorable in vivo pharmacokinetics. Our study demonstrates that aliphatic compounds can be used as a new generation molecular platform for the development of novel melanoma targeting agents. Further evaluation and optimization of 18F-FPDA for melanin targeted molecular imaging are therefore warranted." @default.
• W2009702208 created "2016-06-24" @default.
• W2009702208 creator A5050419694 @default.
• W2009702208 creator A5052737132 @default.
• W2009702208 creator A5053731056 @default.
• W2009702208 creator A5061397387 @default.
• W2009702208 creator A5067589644 @default.
• W2009702208 creator A5075963891 @default.
• W2009702208 creator A5076164674 @default.
• W2009702208 date "2013-08-22" @default.
• W2009702208 modified "2023-10-16" @default.
• W2009702208 title "A Novel Aliphatic ¹⁸F-Labeled Probe for PET Imaging of Melanoma" @default.
• W2009702208 cites W1951046932 @default.
• W2009702208 cites W1973042344 @default.
• W2009702208 cites W1974483691 @default.
• W2009702208 cites W1980199015 @default.
• W2009702208 cites W1986579256 @default.
• W2009702208 cites W1987592466 @default.
• W2009702208 cites W1994294496 @default.
• W2009702208 cites W2012020367 @default.
• W2009702208 cites W2016918536 @default.
• W2009702208 cites W2029221665 @default.
• W2009702208 cites W2034847876 @default.
• W2009702208 cites W2034999592 @default.
• W2009702208 cites W2037055237 @default.
• W2009702208 cites W2037077450 @default.
• W2009702208 cites W2043680485 @default.
• W2009702208 cites W2045202298 @default.
• W2009702208 cites W2051706152 @default.
• W2009702208 cites W2054799426 @default.
• W2009702208 cites W2071765362 @default.
• W2009702208 cites W2088656570 @default.
• W2009702208 cites W2096661340 @default.
• W2009702208 cites W2097776311 @default.
• W2009702208 cites W2108228855 @default.
• W2009702208 cites W2122999546 @default.
• W2009702208 cites W2123073351 @default.
• W2009702208 cites W2129570557 @default.
• W2009702208 cites W2135670695 @default.
• W2009702208 cites W2136277691 @default.
• W2009702208 cites W2152348553 @default.
• W2009702208 cites W2158734599 @default.
• W2009702208 cites W2162046503 @default.
• W2009702208 cites W2166664821 @default.
• W2009702208 cites W2317205041 @default.
• W2009702208 cites W4244068819 @default.
• W2009702208 doi "https://doi.org/10.1021/mp400225s" @default.
• W2009702208 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3946504" @default.
• W2009702208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23927458" @default.
• W2009702208 hasPublicationYear "2013" @default.
• W2009702208 type Work @default.
• W2009702208 sameAs 2009702208 @default.
• W2009702208 citedByCount "19" @default.
• W2009702208 countsByYear W20097022082014 @default.
• W2009702208 countsByYear W20097022082016 @default.
• W2009702208 countsByYear W20097022082017 @default.
• W2009702208 countsByYear W20097022082018 @default.
• W2009702208 countsByYear W20097022082020 @default.
• W2009702208 countsByYear W20097022082022 @default.
• W2009702208 crossrefType "journal-article" @default.
• W2009702208 hasAuthorship W2009702208A5050419694 @default.
• W2009702208 hasAuthorship W2009702208A5052737132 @default.
• W2009702208 hasAuthorship W2009702208A5053731056 @default.
• W2009702208 hasAuthorship W2009702208A5061397387 @default.
• W2009702208 hasAuthorship W2009702208A5067589644 @default.
• W2009702208 hasAuthorship W2009702208A5075963891 @default.
• W2009702208 hasAuthorship W2009702208A5076164674 @default.
• W2009702208 hasBestOaLocation W20097022082 @default.
• W2009702208 hasConcept C107538193 @default.
• W2009702208 hasConcept C136339569 @default.
• W2009702208 hasConcept C150903083 @default.
• W2009702208 hasConcept C177322064 @default.
• W2009702208 hasConcept C185592680 @default.
• W2009702208 hasConcept C202751555 @default.
• W2009702208 hasConcept C207001950 @default.
• W2009702208 hasConcept C2775842073 @default.
• W2009702208 hasConcept C2777658100 @default.
• W2009702208 hasConcept C2777807558 @default.
• W2009702208 hasConcept C2778172261 @default.
• W2009702208 hasConcept C2780231548 @default.
• W2009702208 hasConcept C29331040 @default.
• W2009702208 hasConcept C2989005 @default.
• W2009702208 hasConcept C3017724952 @default.
• W2009702208 hasConcept C40869318 @default.
• W2009702208 hasConcept C502942594 @default.
• W2009702208 hasConcept C55493867 @default.
• W2009702208 hasConcept C71240020 @default.
• W2009702208 hasConcept C71924100 @default.
• W2009702208 hasConcept C86803240 @default.
• W2009702208 hasConceptScore W2009702208C107538193 @default.
• W2009702208 hasConceptScore W2009702208C136339569 @default.
• W2009702208 hasConceptScore W2009702208C150903083 @default.
• W2009702208 hasConceptScore W2009702208C177322064 @default.
• W2009702208 hasConceptScore W2009702208C185592680 @default.
• W2009702208 hasConceptScore W2009702208C202751555 @default.
• W2009702208 hasConceptScore W2009702208C207001950 @default.
• W2009702208 hasConceptScore W2009702208C2775842073 @default.
• W2009702208 hasConceptScore W2009702208C2777658100 @default.

• next